康哲药业(00867.HK)与生物制药公司Biocon就三个仿制药产品签订许可与供应协议
格隆汇9月12日丨康哲药业(00867.HK)公告,本集团通过其全资附属公司于2019年9月12日与Biocon Limited的全资附属公司就其三个仿制药产品签订了许可与供应协议。根据协议的约定,本集团通过其全资附属公司获得了在大中华地区(包括中国大陆、香港特别行政区、澳门特别行政区和台湾)根据Biocon Limited的知识产权注册及商业化产品的独家的许可权利。协议的初始期间为十年,根据协议的约定的特定条件或经双方同意后单个产品可按每次两年的固定期限续期。
根据IQVIA数据,2018年,与产品同活性成分(API)的产品在中国大陆的销售额约为8亿美元。此次合作将使本集团现有的产品组合在产品于区域上市后得以丰富及扩张。
据悉,Biocon Limited于2004年在孟买证券交易所及印度国家证券交易所公开上市,是一家全面整合、创新导向的全球生物制药公司,致力于为慢性疾病(如糖尿病、癌症和自身免疫性疾病)提供价格合理的复杂疗法。Biocon Limited已在印度和其他全球市场开发和商业化了一系列生物类似物、新型生物制剂和差异化小分子。该公司是复杂API的全球领先参与者,在100个国家拥有超过1,000名客户。其正在建立一个利基仿制制剂组合,并已在美国以自己的品牌商业化了仿制制剂。
BioconLimited致力于开发创新分子,以满足未满足的患者需求,并在免疫肿瘤学领域拥有具前景的新资产管线。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.